The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer.
 
Mark H. O'Hara
No Relationships to Disclose
 
Thomas Benjamin Karasic
No Relationships to Disclose
 
Irina Vasilevskaya
No Relationships to Disclose
 
Maryann Redlinger
No Relationships to Disclose
 
Arturo Loaiza-Bonilla
Stock and Other Ownership Interests - Massive Bio
Consulting or Advisory Role - Bayer; Celgene; Genentech; Ipsen; Merrimack
Research Funding - Ipsen (Inst)
 
Ursina R. Teitelbaum
No Relationships to Disclose
 
Bruce J. Giantonio
No Relationships to Disclose
 
Nevena Damjanov
Honoraria - Daiichi Sankyo (I); Sirtex Medical
Consulting or Advisory Role - Amgen; Bayer; Celgene
 
Kim Anna Reiss
No Relationships to Disclose
 
Mark Alan Rosen
No Relationships to Disclose
 
Daniel F Heitjan
No Relationships to Disclose
 
Andrea B. Troxel
Leadership - VAL Health
Consulting or Advisory Role - Asubio Pharma; VAL Health
Research Funding - The Vitality Group (Inst); Weight Watchers (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for "Compositions and Methods for Treating Cutaneous T Cell Lymphoma”
Travel, Accommodations, Expenses - The Vitality Group
 
Ravi K. Amaravadi
No Relationships to Disclose
 
Peter J. O'Dwyer
Consulting or Advisory Role - Bristol-Myers Squibb; Five Prime Therapeutics; Forty Seven; Genentech
Research Funding - Amgen; Bayer; BBI Healthcare; Bristol-Myers Squibb; Celgene; Five Prime Therapeutics; Forty Seven; Genentech; GlaxoSmithKline; Merck; Mirati Therapeutics; Novartis; Pfizer; Pharmacyclics